OCS
Oculis Holding AG Ordinary sharesNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.78B
P/E Ratio
—
EPS
$-2.15
Beta
0.20
52W High
$34.48
52W Low
$16.00
50-Day MA
$27.52
200-Day MA
$23.02
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Oculis Holding AG Ordinary shares
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company is headquartered in Zug, Switzerland.
Fundamentals
| Revenue (TTM) | $1.12M |
| Gross Profit (TTM) | $-55.96M |
| EBITDA | $-83.36M |
| Operating Margin | -10396.00% |
| Return on Equity | -52.70% |
| Return on Assets | -23.30% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $4.32 |
| Price-to-Book | 7.12 |
| Price-to-Sales (TTM) | 1585.79 |
| EV/Revenue | - |
| EV/EBITDA | -3.47 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -26.70% |
| Shares Outstanding | $60.39M |
| Float | $49.64M |
| % Insiders | 3.51% |
| % Institutions | 37.91% |
Historical Volatility
HV 10-Day
84.86%
HV 20-Day
71.57%
HV 30-Day
62.56%
HV 60-Day
54.74%
HV Rank
100.0%
Volatility is currently expanding
Analyst Ratings
Consensus ($52.12 target)
3
Strong Buy7
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026